Phase I/II Study of Subcutaneously Administered Veltuzumab (hA20) in Patients With CD20+ Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase of Trial: Phase I/II
Latest Information Update: 01 Jan 2016
At a glance
- Drugs Veltuzumab (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Immunomedics
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Sep 2011 Planned end date changed from 31 Dec 2009 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 04 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.